RegenXBio Statistics
Want to see RGNX full AI Analyst Report?
RegenXBio (RGNX) Stock Statistics & Valuation Metrics
Total Valuation
RegenXBio has a market cap or net worth of $560.06M. The enterprise value is $492.45M.
- Market Cap
- $560.06M
- Enterprise Value
- $492.45M
Share Statistics
RegenXBio has 66,122,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 66,122,600
- Owned by Insiders
- 7.27%
- Owned by Institutions
- 29.47%
Financial Efficiency
RegenXBio’s return on equity (ROE) is -1.89 and return on invested capital (ROIC) is -42.11%.
- Return on Equity (ROE)
- -1.89
- Return on Assets (ROA)
- -0.43
- Return on Invested Capital (ROIC)
- -42.11%
- Return on Capital Employed (ROCE)
- -0.48
- Revenue Per Employee
- 459.41K
- Profits Per Employee
- -522.58K
- Employee Count
- 371
- Asset Turnover
- 0.38
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of RegenXBio is -2.51. RegenXBio’s PEG ratio is 0.09.
- PE Ratio
- -2.51
- PS Ratio
- 3.46
- PB Ratio
- 3.55
- Price to FCF
- -3.44
- Price to Operating Cash Flow
- -3.46
- PEG Ratio
- 0.09
Income Statement
In the last 12 months, RegenXBio had revenue of 170.44M and earned -193.88M in profits. Earnings per share was -3.76.
- Revenue
- 170.44M
- Gross Profit
- 150.14M
- Operating Income
- -161.20M
- Pretax Income
- -193.88M
- Net Income
- -193.88M
- EBITDA
- -133.25M
- Earnings Per Share (EPS)
- -3.76
Cash Flow
In the last 12 months, operating cash flow was -152.10M and capital expenditures -2.70M, giving a free cash flow of -154.80M billion.
- Operating Cash Flow
- -152.10M
- Free Cash Flow
- -154.80M
- Free Cash Flow per Share
- -2.37
Dividends & Yields
RegenXBio pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -30.64%
- Earnings Yield
- -35.14%
Stock Price Statistics
- Beta
- 2.37
- 52-Week Price Change
- -30.78%
- 50-Day Moving Average
- 7.71
- 200-Day Moving Average
- 8.88
- Relative Strength Index (RSI)
- 55.02
- Average Volume (3m)
- 1.39M
Important Dates
RegenXBio upcoming earnings date is Mar 02, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 02, 2027
- Ex-Dividend Date
- ―
Financial Position
RegenXBio as a current ratio of 2.38, with Debt / Equity ratio of 253.59%
- Current Ratio
- 2.38
- Quick Ratio
- 2.38
- Debt to Market Cap
- 0.26
- Net Debt to EBITDA
- -1.70
- Interest Coverage Ratio
- -3.58
Taxes
In the past 12 months, RegenXBio has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
RegenXBio EV to EBITDA ratio is -3.84, with an EV/FCF ratio of -3.07.
- EV to Sales
- 3.09
- EV to EBITDA
- -3.84
- EV to Free Cash Flow
- -3.07
- EV to Operating Cash Flow
- -3.13
Balance Sheet
RegenXBio has $250.98M in cash and marketable securities with $66.55M in debt, giving a net cash position of $184.43M billion.
- Cash & Marketable Securities
- $250.98M
- Total Debt
- $66.55M
- Net Cash
- $184.43M
- Net Cash Per Share
- $2.79
- Tangible Book Value Per Share
- $2.27
Margins
Gross margin is 87.54%, with operating margin of -95.68%, and net profit margin of -113.85%.
- Gross Margin
- 87.54%
- Operating Margin
- -95.68%
- Pretax Margin
- -113.85%
- Net Profit Margin
- -113.85%
- EBITDA Margin
- -80.55%
- EBIT Margin
- -90.30%
Analyst Forecast
The average price target for RegenXBio is $20.91, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $20.91
- Price Target Upside
- 160.39% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 11
- Revenue Growth Forecast
- -4.59%
- EPS Growth Forecast
- 8.03%
Scores
- Smart Score
- 9
- AI Score
- 50
